Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dominik Fischer, who completed his DPhil in our Department, received an extraordinary professorship at the Eberhard Karls University of Tübingen on Tuesday 7 July 2015.

In this clinical academic position, he will continue his work on retinal gene therapy at the Centre for Ophthalmology, Tübingen.

Dominik has been involved in pre-clinical and clinical gene therapy programmes in Professor Robert MacLaren’s group as MRC Clinical Research Training Fellow since 2012.

Professor Dominik Fischer is principal investigator of the first clinical retinal gene therapy trials in Germany with his team at the Universty Eye Hospital Tübingen.

Similar stories

New genetic diagnosis technology for eye disease receives major funding award

Eye2Gene explores the use of AI to determine which genetic condition is causing a patient’s inherited retinal disease, by examining eye scans.

How our dreams changed during the COVID-19 pandemic

This study explored associations between COVID-19 and dream recall frequency, and related social, health, and mental health factors.

New insights into the effect of exposure to dim light in the evening on the biology of the sleep-wake cycle

A new study has revealed more about how exposure to dim light in the evening affects circadian health. The findings emphasise the need to optimise our artificial light exposure if we are to avoid shifting our biological clocks.

International study finds insomnia, anxiety and depression very prevalent during first phase of COVID-19 pandemic

Researchers are recommending public health interventions to reduce the long-term adverse outcomes associated with chronic insomnia and mental health problems.